Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Vericel Corporation

VCELNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Jul 30, 2026Accepted Jul 30, 2026, 10:56 AM EDTFiling CIK 887359Accession 0001959173-26-005454
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
Vericel Corp
Issuer CIK
0000887359
SEC file number
001-35280
Phone
6175885555
Person for whose account securities are to be sold
SIEGAL JONATHAN
Relationships to issuer
Officer
Street
25 BLUE SKY DRIVE
City
BURLINGTON
State / country code
MA
Postal code
01803

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common4,500220,050.0051,206,61407/30/2026NASDAQFidelity Brokerage Services LLC

Broker / market maker — proposed row 1, entry 1

Name
Fidelity Brokerage Services LLC
Street
900 Salem Street
City
Smithfield
State / country code
RI
Postal code
02917

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common07/30/2026Stock Option ExerciseIssuer4,500N07/30/2026Cash

Sales reported in the preceding three months

Sales reported in the preceding three months · 3 reported rows
SellerSecuritySale dateAmount soldGross proceeds
Jonathan SiegalCommon05/06/20263,433130,454.00
Jonathan SiegalCommon05/07/20261,42257,591.00
Jonathan SiegalCommon06/26/20262,732122,666.80

Seller — prior-sale row 1, entry 1

Name
Jonathan Siegal
Street
25 Blue Sky Drive
City
Burlington
State / country code
MA
Postal code
01803

Seller — prior-sale row 2, entry 1

Name
Jonathan Siegal
Street
25 Blue Sky Drive
City
Burlington
State / country code
MA
Postal code
01803

Seller — prior-sale row 3, entry 1

Name
Jonathan Siegal
Street
25 Blue Sky Drive
City
Burlington
State / country code
MA
Postal code
01803

Prior-sale reporting

Nothing to report for the preceding three months
N

Notice signature

Notice date
07/30/2026
Signed
/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jonathan D. Siegal
Plan adoption dates
12/10/2025

Company context

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. For more information, please visit www.vcel.com.

Current securities

Recent company filings

  1. 4 filingAug 14, 2026
  2. SCHEDULE 13G/A - filed by Soleus Capital Master Fund, L.P. regarding Vericel CorpAug 13, 2026
  3. 144 filingAug 12, 2026
  4. 4 filingAug 5, 2026
  5. 144 filingAug 3, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.